AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

August 31, 2009

Study Completion Date

January 31, 2012

Conditions
Ovarian NeoplasmsOvarian Cancer
Interventions
DRUG

AZD0530

oral once daily dose

DRUG

Carboplatin

intravenous injection

DRUG

Paclitaxel

intravenous infusion

Trial Locations (50)

Unknown

Research Site, Pleven

Research Site, Plovdiv

Research Site, Sofia

Research Site, Varna

Research Site, Edmonton

Research Site, Vancouver

Research Site, St. John's

Research Site, Ottawa

Research Site, Toronto

Research Site, Montreal

Research Site, Québec

Research Site, Sherbrooke

Research Site, Aalborg

Research Site, Herning

Research Site, Næstved

Research Site, Paris

Research Site, Avignon

Research Site, Bordeaux

Research Site, Caen

Research Site, Lyon

Research Site, Montpellier

Research Site, Nantes

Research Site, Pierre-Bénite

Research Site, Reims

Research Site, Vandœuvre-lès-Nancy

Research Site, Amsterdam

Research Site, Leiden

Research Site, Nijmegen

Research Site, The Hague

Research Site, Bergen

Research Site, Oslo

Research Site, Lima

Research Site, Coimbra

Research Site, Funchal

Research Site, Lisbon

Research Site, Porto

Research Site, Baia Mare

Research Site, Alba Iulia

Research Site, Bucharest

Research Site, Cluj-Napoca

Research Site, Kazan'

Research Site, Moscow

Research Site, Nizhny Novgorod

Research Site, Saint Petersburg

Research Site, Córdoba

Research Site, Barcelona

Research Site, Hospitalet Dellobregat(barcelo

Research Site, Madrid

Research Site, Valencia

Research Site, Coventry

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY